Abeona Therapeutics Inc. (ABEO) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Abeona Therapeutics Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
High 5.86 at 7:45 am ET, low 5.57 at 10:00 am ET.
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
the bull case· 3
127
managers reporting a position in institutional regulatory filings
13fJun 30 '26+4.82%
largest reporting managers net change in shares over the latest quarter
13fJun 30 '2622
managers whose positions together make up most of the reported value
13fJun 30 '26the bear case· 4
8 of 8
recent reports where the move came in under options implied ranges
earnings historyimplied vs realized3
funds on file reporting a position in the company
n-portas of Jun 30 '260.01%
share of an index ETF's assets representing the largest fund weight on file
n-portJun 30 '267 of 23
largest reporting managers that cut their stake in the latest quarter
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 13 '26 report. Not a forecast, not advice.
Of the 6 companies Abeona Therapeutics Inc. moves with most closely, none share its SEC classification.
Measured against 500 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
tall tick = annual report · 1 on record
126 managers report a position worth $254.1M between them, and 22 of them hold 80% of it.
ABEO (Abeona Therapeutics Inc.) has 0 disclosed suppliers and 1 disclosed customers, strongest disclosure first.
Customers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.